The Supreme Court Just Changed the Rules for Roundup Cancer Claims — But It Did Not Close the Courthouse Door
If you used Roundup and later developed non-Hodgkin’s lymphoma, you are reading this at a moment the ground just shifted under your feet. On June 25, 2026, the United States Supreme Court ruled 7-2 that federal law blocks state-court lawsuits claiming the maker of Roundup failed to warn about cancer risks. Thousands of pending cases — roughly 200,000 claims filed nationwide against Bayer AG and its subsidiary Monsanto — just lost their primary legal theory. If you are one of those people, or someone who was about to file, you need to know exactly what the ruling does, what it does not do, and what legal paths remain open. We are going to tell you all of it — straight, without sugarcoating, and with the specificity your decision demands.
The ruling blocks one theory: failure to warn. It does not block every theory. The Supreme Court’s own opinion left the door open to design defect claims — the argument that Roundup’s formulation containing glyphosate was unreasonably dangerous as designed, regardless of what the label said. A $7.25 billion class-action settlement is still proceeding in Missouri state court. And Bayer itself has already removed glyphosate from residential Roundup products sold in the United States — a voluntary corporate decision that may be the single most powerful piece of evidence in a design defect case. We are a trial firm that takes toxic tort cases in Missouri, and we built this page to give you the complete picture of where Roundup litigation stands today and what your options are.
What the Supreme Court Ruling Actually Does — and What It Does Not Do
The Supreme Court held that under the Federal Insecticide, Fungicide, and Rodenticide Act — the federal law that governs pesticide registration and labeling in the United States — state courts cannot impose labeling requirements on pesticide products that are different from or in addition to those required under federal law. Because the Environmental Protection Agency approved Roundup’s label without requiring a cancer warning, having determined that glyphosate is “not likely” to cause cancer in humans when used as directed, the Court ruled that state-law failure-to-warn claims are preempted. A jury in St. Louis had awarded a Missouri resident $1.25 million on exactly that theory — that Monsanto failed to warn him about potential cancer dangers — but he never received the money because the case was appealed, and now that theory has been foreclosed by the highest court in the country.
But here is what the ruling did not do. It did not say Roundup is safe. It did not say glyphosate does not cause cancer. It did not say Bayer and Monsanto cannot be sued at all. And it explicitly left room for other claims, including design defect lawsuits — the theory that the product itself was unreasonably dangerous in its formulation, independent of any labeling failure. The plaintiff in the Supreme Court case has publicly said he is considering bringing a new case on different grounds.
“The ruling still leaves room for other lawsuits alleging problems with the product’s design.”
That sentence — from the reporting of the decision itself — is the most important sentence a person in your situation can read. The courthouse door did not slam shut. One hallway was blocked. Others remain open.
The Defendant: Bayer AG and Monsanto — A Corporate Structure Built to Contain Liability
Bayer AG is a German pharmaceutical and agrochemical conglomerate that acquired Monsanto Company in 2018 for $63 billion. At the time of the acquisition, Monsanto was the original developer, manufacturer, and marketer of Roundup and its active ingredient, glyphosate. Bayer inherited a tidal wave of litigation — approximately 200,000 claims, mostly from home users who sprayed Roundup on their lawns and gardens for years and later developed non-Hodgkin’s lymphoma. Bayer has set aside $16 billion in total for settlements, and earlier this year proposed a $7.25 billion class-action settlement that a federal judge ruled will be heard in Missouri state court.
The corporate structure matters for your case. Monsanto is the entity that designed the product, controlled the formulation, ran the EPA registration strategy, and held the internal safety research. Bayer is the parent with the deep pockets, the global revenue, and the post-acquisition litigation strategy — including the state-level lobbying campaign that has persuaded North Dakota, Georgia, and Kentucky to pass laws shielding the company from failure-to-warn liability. Any lawsuit must name the right entity or entities — and the right entity depends on which legal theory you pursue.
For design defect claims, entities in the chain of distribution may also face liability — the retailers, distributors, and sellers who put the product into consumers’ hands. Whether those entities are shielded by the same federal preemption doctrine is an open question that depends on state product liability law and the specific theory pleaded. This is where naming the correct defendants — and naming all of them — becomes foundational work.
Bayer’s own CEO, Bill Anderson, said the ruling “provides the regulatory clarity necessary for innovators like us to develop the agricultural tools that guarantee an affordable food supply.” That is a corporate victory speech. What it does not mention is that Bayer itself voluntarily removed glyphosate from Roundup sold in the U.S. residential lawn and garden market — a decision that predates the Supreme Court ruling and that a skilled trial lawyer can frame as a corporate admission that the original design was something the company was no longer willing to defend.
What FIFRA Preemption Means in Plain Language
The Federal Insecticide, Fungicide, and Rodenticide Act — known as FIFRA — is the federal statute that governs how pesticides are registered, labeled, and sold in the United States. Under FIFRA, a manufacturer cannot sell a pesticide until the EPA reviews the product, evaluates its safety, and approves the label — the set of warnings, directions, and precautions that appears on the container. The EPA reviewed Roundup and approved a label that did not include a cancer warning, having concluded that glyphosate is “not likely” to cause cancer in humans when used as directed.
FIFRA contains an express preemption provision that bars states from imposing labeling requirements that are “in addition to or different from” those required under federal law. The Supreme Court’s majority, in an opinion written by Justice Brett Kavanaugh, held that this provision means state courts cannot compel Monsanto to add a cancer warning to Roundup’s label — because the EPA specifically decided not to require one, and federal law says states cannot override that decision.
The dissenting justices — Justice Ketanji Brown Jackson, joined by Justice Neil Gorsuch — argued that Monsanto could have added a cancer warning on its own without violating federal law, and that FIFRA did not block state tort claims. That dissent is more than a disagreement. It is a roadmap for the legal arguments that will shape the next phase of Roundup litigation, particularly as plaintiffs pivot to design defect and other non-labeling theories.
The conflict at the heart of this case is not going away. The World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic” in 2015. The EPA reached the opposite conclusion. That scientific disagreement — between the world’s leading cancer authority and the U.S. regulatory agency — remains the central tension in every Roundup case, and it is a tension a jury can be asked to weigh in a design defect trial even after the failure-to-warn door has closed.
Design Defect Claims: The Legal Path That Remains Open
A design defect claim does not ask whether the label was adequate. It asks whether the product itself — its formulation, its chemical composition, the way it was designed to work — was unreasonably dangerous. In Missouri and most states, a product is defective in design if it was unreasonably dangerous as designed and a safer, feasible alternative design existed. For Roundup, that means proving two things: that the glyphosate-based formulation posed an unreasonable cancer risk to users, and that a safer alternative — a different formulation, a different active ingredient, a product that achieved the same weed-killing result without the carcinogenic concern — was technologically and economically feasible.
The Supreme Court ruling did not touch this theory. Design defect claims are not labeling claims. They do not ask the manufacturer to add a warning. They ask whether the manufacturer should have designed a different product. FIFRA’s preemption provision bars states from imposing different labeling requirements — it does not bar states from holding a manufacturer accountable for putting an unreasonably dangerous product into the stream of commerce.
Here is where Bayer’s voluntary reformulation becomes powerful evidence. Bayer removed glyphosate from Roundup sold in the U.S. residential lawn and garden market. It did this while telling farmers that agricultural Roundup is safe and while fighting in court that glyphosate does not cause cancer. A trial lawyer can argue to a jury: if this product was safe, why did you take the chemical out? If there was no cancer risk, why did you reformulate? If the EPA said it was fine, why did you change the formula for home users? The company’s own conduct — not a regulatory ruling, not a scientific abstract — may be the most persuasive evidence a jury hears.
Missouri’s product liability framework is favorable for design defect claims. Missouri follows the Restatement approach to product liability, which recognizes design defect as a viable theory. Missouri does not impose general caps on non-economic damages in product liability cases — meaning a jury has full discretion to award what it believes is fair for pain, suffering, emotional distress, and loss of quality of life. And Missouri follows pure comparative fault, which means even if a plaintiff is found partly at fault — for using the product without gloves, for spraying on a windy day, for not reading the directions — their recovery is reduced by their percentage of fault but is never entirely barred. Every percentage point the defense tries to pin on the plaintiff is money, which is exactly why the defense works so hard to manufacture those points.
The expert witnesses a design defect case requires are different from a failure-to-warn case. You need board-certified hematologist-oncologists who can testify to specific causation — that this person’s non-Hodgkin’s lymphoma was caused by glyphosate exposure. You need toxicologists and epidemiologists for general causation — that glyphosate can cause non-Hodgkin’s lymphoma in humans. You need industrial hygienists who can reconstruct the plaintiff’s exposure — how much they sprayed, how often, for how many years, and what dose they received. And you need product design experts who can testify that a safer alternative formulation was feasible at the time the product was sold. Each of these experts is a separate discipline, and the case rises or falls on whether they can present a unified, coherent causal chain from product to exposure to disease.
The $7.25 Billion Class-Action Settlement: What It Is and Who Qualifies
While the Supreme Court ruling blocks failure-to-warn lawsuits, Bayer has said it plans to proceed with a proposed $7.25 billion class-action settlement intended to resolve many of the remaining claims. A federal judge recently ruled that the proposed settlement will be heard in Missouri state court — where many of the lawsuits have been filed and where the legal landscape has historically been favorable to plaintiffs in mass tort cases.
The settlement exists within Bayer’s broader $16 billion reserve set aside for Roundup litigation. It is a structured compensation framework — not a blank check. Settlement values per claimant will vary significantly based on exposure duration, cancer subtype, treatment history, and other factors that determine which “tier” a claimant falls into. For some claimants, settlement participation may offer a faster, more certain path to compensation than a design defect lawsuit. For others — particularly those with strong exposure histories, compelling medical records, and facts that support a design defect theory — individual litigation may carry a higher potential ceiling.
The trade-off is real. Settlement participation offers structured compensation without the risk, cost, and uncertainty of trial. But it also requires giving up the right to sue individually, and the release scope — what claims you give up in exchange for payment — must be examined with extreme care. Opt-out deadlines, tier classifications, and the scope of the release are the three critical variables. Missing an opt-out deadline can trap a claimant in a settlement whose terms may undervalue their specific case. A claimant who opts out preserves their right to sue but gives up the guaranteed payment and faces a design defect case that is harder and more expensive than a failure-to-warn case would have been.
Every person considering the settlement needs an individualized evaluation. The settlement is not a one-size-fits-all solution, and it was not designed to be. It was designed to resolve the bulk of claims efficiently — which means it is structured to appeal to the median claimant, not the outlier with the strongest case.
Missouri Law: Why St. Louis Became the Center of Roundup Litigation
The underlying Supreme Court case came from St. Louis, Missouri. The plaintiff was a Missouri resident who served as his historic neighborhood association’s groundskeeper — the “spray guy” — applying Roundup to community parks for more than twenty years before developing non-Hodgkin’s lymphoma. Missouri has been a prominent venue for Roundup litigation, with Missouri state courts handling a significant portion of the approximately 200,000 claims filed nationwide. The proposed $7.25 billion class-action settlement is slated to be heard in Missouri state court.
Missouri’s legal framework is one of the reasons it became a Roundup litigation hub. Missouri’s personal injury statute of limitations is five years — among the longest in the nation. Most states give you two or three years to file a personal injury lawsuit. Missouri gives you five. That longer window has drawn filings from plaintiffs across the country and has allowed claims to survive that would have been time-barred in other states.
For toxic tort cases specifically, the discovery rule may extend the clock further. The discovery rule holds that the statute of limitations does not begin to run until the plaintiff knew — or through reasonable diligence should have known — both that they were injured and that the injury was caused by the defendant’s product. For a disease like non-Hodgkin’s lymphoma, which can develop years or decades after exposure, the question of when the clock started is often contested. A person diagnosed with NHL in 2023 who used Roundup from 1995 to 2015 may not have connected their disease to glyphosate exposure until reading about the litigation — and the law in many jurisdictions says the clock starts at discovery, not at exposure or diagnosis alone.
Missouri follows pure comparative fault. Your recovery is reduced by your percentage of fault but is never barred entirely. If a jury finds you 30 percent at fault for not wearing protective equipment while spraying, your award is reduced by 30 percent — you still recover 70 percent. This is more favorable than the modified comparative fault rules in many states, which bar recovery entirely if the plaintiff’s fault exceeds 50 or 51 percent.
Missouri does not impose general caps on non-economic damages in product liability cases. This distinguishes Missouri from tort-reform states that limit what a jury can award for pain and suffering, emotional distress, and loss of quality of life. In Missouri, the jury’s discretion on those damages is preserved — which is a significant advantage in a cancer case where the human toll is enormous and the medical bills are only part of the story.
Three states — North Dakota, Georgia, and Kentucky — have enacted legislation shielding Bayer from failure-to-warn liability, creating a patchwork of state-level protections on top of the federal preemption ruling. If you live in one of those states, the legal landscape is even more restricted, and the design defect path may be your only viable theory. If you live in Missouri or a state without such a shield, your options are broader but still narrowed by the Supreme Court’s preemption holding.
The Medicine: Non-Hodgkin’s Lymphoma and Glyphosate Exposure
Non-Hodgkin’s lymphoma is a cancer of the lymphatic system — the network of vessels, nodes, and organs that carries infection-fighting white blood cells throughout the body. It begins when lymphocytes, a type of white blood cell, develop genetic mutations that cause them to grow abnormally and multiply uncontrollably. Unlike normal lymphocytes, which die when their job is done, cancerous lymphocytes persist and accumulate, forming tumors in lymph nodes, spleen, bone marrow, and other lymphoid tissues.
The treatment is aggressive. Depending on the subtype and stage, it may include chemotherapy regimens — combinations of drugs administered in cycles over weeks or months, each cycle bringing nausea, fatigue, hair loss, immunosuppression, and the risk of secondary infections. Radiation therapy may target specific lymph node regions. Immunotherapy uses the body’s own immune system to fight the cancer, and stem cell transplants may be necessary for aggressive or relapsed cases — a procedure that involves high-dose chemotherapy to destroy the bone marrow, followed by infusion of healthy stem cells, weeks of hospitalization in protective isolation, and months of recovery.
The medical costs can reach hundreds of thousands of dollars. Even after treatment ends — even in remission, as the plaintiff in the Supreme Court case reported his cancer to be — ongoing surveillance is required. CT scans, blood tests, and follow-up appointments continue for years, because non-Hodgkin’s lymphoma can relapse. The psychological toll — the fear of recurrence, the anxiety before every scan, the life reorganized around a disease that may or may not come back — is its own injury, one that no bill fully captures.
The proof problem the defense exploits in these cases is specific causation. Non-Hodgkin’s lymphoma has many potential causes — genetic factors, viral infections, other chemical exposures, immune system disorders. The defense will argue that the plaintiff’s cancer was idiopathic — meaning it arose spontaneously, without a known cause — or that it was caused by something other than glyphosate. The counter requires expert testimony that links the plaintiff’s specific exposure history, dose, and disease characteristics to glyphosate, using the IARC classification, peer-reviewed epidemiological studies, and the plaintiff’s own medical and exposure records. The IARC’s 2015 classification of glyphosate as “probably carcinogenic” is foundational — it is the world’s leading cancer authority saying this chemical probably causes cancer in humans, and it creates the scientific framework within which specific causation can be argued.
The latency between exposure and diagnosis is years — often decades. A person who sprayed Roundup on their lawn every weekend from 1995 to 2010 and was diagnosed with non-Hodgkin’s lymphoma in 2022 had a thirty-year relationship with this product. That latency is the defense’s friend on statute of limitations questions and the plaintiff’s friend on the discovery rule — it cuts both ways, which is why the timing analysis must be precise and case-specific.
The Evidence Clock: What Proof Exists and How Fast It Dies
Every piece of evidence in a Roundup cancer case is on a timer. Some of it is on a very short timer. The moment you suspect your cancer may be connected to Roundup exposure, evidence preservation becomes the single most urgent task — because the records that prove your case are the same records that can be legally destroyed, discarded, or lost if no one demands they be saved.
Medical records are the foundation. You need pathology reports confirming the non-Hodgkin’s lymphoma diagnosis, treatment records documenting chemotherapy regimens and their dates, imaging studies showing disease progression or remission, and follow-up surveillance records. Provider retention policies vary — older records may be archived, purged, or stored in systems that are difficult to access. Obtain your complete medical file immediately, not just the summary. The pathology report is irreplaceable — it contains the specific NHL subtype, which affects both causation analysis and settlement tier classification.
Exposure history documentation is the second pillar and the one that dies fastest. This includes employment records, neighborhood association records, purchase receipts for Roundup products, application logs, and witness statements from people who saw you use the product. Memories fade. Witnesses relocate or pass away. Organizational records — like the neighborhood association records that documented the Supreme Court case plaintiff’s role as the “spray guy” — may be discarded when officers change or organizations restructure. Every month that passes without documenting your exposure history is a month of degraded evidence. Write down everything you remember now: which Roundup product you used, how often you applied it, what years, what areas, what equipment you used, whether you wore protective gear, and who else was present.
Product samples, lot numbers, and historical formulation records are critical for design defect claims. The specific formulation and concentration of the glyphosate-based product you applied matters — and Bayer has reformulated residential Roundup without glyphosate, making older product samples and formulation data increasingly difficult to obtain. If you still have an old container of Roundup, do not discard it. If you have receipts showing the specific product you purchased, preserve them. The lot number on a container can tie your specific product to a specific formulation and manufacturing batch.
Internal Monsanto and Bayer corporate documents — safety research, adverse findings, marketing strategy, labeling decisions, internal communications about cancer risk — are the evidence that transforms a design defect case from a scientific argument into a corporate accountability argument. Some of these documents have already been produced in prior multidistrict litigation discovery. Others may be subject to litigation hold once a case is filed. But pre-filing retention and destruction policies may reduce the available universe of documents, and the company controls what it has kept and what it has allowed to disappear. The discovery process is where these documents are forced into the light — but only if a case is filed before the company can narrow the record.
EPA registration files, regulatory correspondence, and labeling history for Roundup products are generally stable and accessible through Freedom of Information Act requests and agency dockets. These records may reveal gaps in the EPA’s review — what the agency considered, what it did not consider, what data Monsanto provided and what it withheld — that support a design defect framework by showing the regulatory approval was less thorough than the public was led to believe.
The IARC monograph and peer-reviewed scientific literature on glyphosate carcinogenicity are stable. The published scientific record does not disappear. But ongoing research may supplement or complicate the evidentiary landscape, and the specific studies your experts rely on must be current and defensible against the defense’s own expert panel.
The preservation letter — the formal demand that a company save all records related to your claim — is the mechanism that stops evidence from dying. It goes out the day you call a lawyer. Not the week after. Not the month after. The day. Because every day the letter is not on file is a day the company can legally destroy records under its own retention schedule, and a day that witnesses’ memories degrade, and a day that old product containers get thrown out in a garage cleaning.
What Your Case May Be Worth After the Ruling
The Supreme Court ruling bifurcated the value landscape of Roundup claims into two distinct tiers, and understanding which tier you fall into is essential to making an informed decision.
Settlement participation — the $50,000 to $300,000 range. For claimants with documented non-Hodgkin’s lymphoma and moderate exposure history, the $7.25 billion class-action settlement framework provides structured compensation based on injury tier and exposure profile. The preemption ruling eliminated failure-to-warn leverage, which reduces the settlement’s per-claimant value compared to what it might have been before the Supreme Court acted. But the settlement fund exists, it is proceeding in Missouri state court, and it offers a path to compensation that does not require proving a design defect case at trial. For claimants whose exposure history is harder to document, or whose medical records are less clear on specific causation, or who cannot face the years of litigation a design defect case demands, the settlement may be the rational choice.
Design defect verdict — the $2 million to $50 million+ range. A design defect verdict in a favorable venue with strong specific causation evidence, compelling internal corporate documents demonstrating knowledge of cancer risk, and punitive damages can reach the level of the pre-ruling multibillion-dollar Roundup verdicts that made this litigation famous. But the legal difficulty and cost have materially increased. The failure-to-warn theory was simpler to explain to a jury: the company knew about a risk and did not put a warning on the label. Design defect is more complex: you must prove the product was unreasonably dangerous as designed, that a safer alternative was feasible, and that the specific formulation caused this specific person’s cancer — all without the labeling argument that drove many of the prior large verdicts. The verdict ceiling is still there. The path to it is steeper, longer, and more expensive.
The $1.25 million verdict the St. Louis plaintiff won — and never collected — represents a modest failure-to-warn recovery. Other Roundup cases produced multibillion-dollar verdicts, reflecting both the severity of non-Hodgkin’s lymphoma and jury reactions to alleged corporate knowledge of cancer risk. Those verdicts were won on failure-to-warn theories that are now preempted. The design defect verdicts of the future will be built differently — on formulation evidence, alternative design feasibility, corporate document discovery, and the company’s own decision to remove glyphosate from residential products.
Punitive damages remain theoretically available under design defect theories if a plaintiff can demonstrate that Monsanto knew of cancer risks and continued marketing glyphosate products. The preemption ruling narrows the evidentiary pathway — you can no longer argue the company should have warned and chose not to — but it does not eliminate punitive exposure if you can prove the company knew the design itself was dangerous and marketed it anyway. The internal corporate documents are the key. If discovery produces memos showing Monsanto scientists raised cancer concerns internally and were overruled by business decisions, that evidence supports both design defect liability and the kind of corporate misconduct that drives punitive awards.
Every case value figure stated here is a framework, not a prediction. The actual value of your claim depends on your exposure profile, your cancer subtype, your treatment history, your age and earning capacity, the venue, the strength of your corporate document discovery, and the legal path you choose. Past results depend on the facts of each case and do not guarantee future outcomes. The one thing we can tell you with certainty is that the value of your case is not zero — even after the Supreme Court ruling, even after the preemption of failure-to-warn claims. The value has shifted, not vanished.
The Defense Playbook: What Bayer’s Lawyers Will Do Next
The defense strategy after the Supreme Court ruling is predictable, because Bayer has already telegraphed it. Here are the plays and the counters.
Play 1: “Your claim is preempted — go away.” Bayer will argue that the Supreme Court ruling blocks all Roundup claims, not just failure-to-warn claims. They will send letters to pending plaintiffs saying the ruling requires dismissal of their cases. They will file motions to dismiss new cases on preemption grounds.
The counter: design defect claims are not labeling claims. The Supreme Court opinion itself left room for design defect theories. A properly pleaded design defect complaint does not ask for a different label — it asks whether the product was unreasonably dangerous as designed. FIFRA’s preemption provision bars states from imposing different labeling requirements. It does not bar states from imposing tort liability for unreasonably dangerous product designs. The legal argument must be precise — a complaint that drifts into labeling territory will be preempted, but a complaint that stays squarely on design is a different animal.
Play 2: “The EPA said it’s safe.” Bayer will lean on the EPA’s determination that glyphosate is “not likely” to cause cancer in humans when used as directed. They will argue that regulatory approval is a complete defense.
The counter: the EPA’s determination is not the final word on safety, and it is not a finding that the product is safe — it is a regulatory decision about labeling requirements under a specific statutory framework. The IARC — the world’s leading cancer authority — reached the opposite conclusion. A jury can be told about both determinations and asked to weigh the evidence. The conflict between the EPA and the WHO is not a reason to dismiss a case — it is a reason to let a jury decide which conclusion is more credible. And the question “if the EPA said it was safe, why did you take glyphosate out of residential Roundup?” is one the company will have to answer under oath.
Play 3: “Take the settlement or get nothing.” Bayer will use the preemption ruling as leverage to push claimants into the $7.25 billion settlement at reduced values, arguing that the alternative is a costly design defect case with uncertain odds.
The counter: the settlement is an option, not an obligation. Every claimant has the right to evaluate the settlement against their individual case value and to opt out if the settlement undervalues their claim. The decision requires an individualized analysis — exposure history, cancer subtype, treatment costs, lost earnings, the strength of the design defect theory for your specific facts, and the venue. A claimant with twenty years of heavy residential Roundup use, a confirmed NHL diagnosis, and a strong exposure narrative may be worth materially more in individual litigation than the settlement tier offers. A claimant with lighter exposure and a less clear causation picture may be better served by the settlement. The one-size-fits-all pitch is designed to benefit the company, not the claimant.
Play 4: “Your cancer wasn’t caused by Roundup.” The defense will argue specific causation — that non-Hodgkin’s lymphoma has many causes, that the plaintiff’s cancer was idiopathic, that the exposure was too low or too long ago to matter.
The counter: the IARC classification, peer-reviewed epidemiological studies, dose reconstruction by industrial hygiene experts, and the plaintiff’s own exposure and medical records together build the causal chain. The defense’s “idiopathic” argument is a burden-shifting trick — they argue that because NHL can arise without a known cause, the plaintiff cannot prove this particular NHL was caused by glyphosate. But the absence of another identified cause, combined with documented exposure to a probable human carcinogen, is itself evidence of specific causation. The expert testimony must be tight, current, and defensible against the defense’s own panel — but the science is not the defense’s strongest front.
Play 5: Delay. Bayer will use every procedural tool — motions to dismiss, motions for summary judgment, Daubert challenges to expert witnesses, venue disputes — to extend the timeline. The longer a case sits, the more evidence degrades, the more witnesses disappear, and the more claimants give up or accept low settlement offers out of exhaustion.
The counter: speed. The preservation letter goes out the day you call. The complaint is filed before the evidence clock runs further. The expert witnesses are retained early. The discovery demands are specific and aggressive. Delay is the defense’s weapon, and speed is the only answer to it. You can learn more about what not to say to an insurance adjuster from our resource library — because the first call from the other side is where the delay game begins.
How a Design Defect Case Is Actually Built
Here is the chronological walk of how a post-ruling Roundup design defect case is built, from the day you call to the day a number is put in front of a jury.
Week one: the preservation letter. The day you call, a formal litigation hold and evidence preservation demand goes to Bayer, Monsanto, and any entities in the chain of distribution. The letter demands preservation of all documents related to glyphosate safety research, internal communications about cancer risk, marketing materials, labeling decisions, product formulation records, and any documents related to the decision to remove glyphosate from residential Roundup. The letter also demands preservation of any product samples, formulation records, and EPA correspondence. This letter creates a legal obligation — if the company destroys evidence after receiving it, the consequences range from adverse inference instructions to sanctions.
Weeks two through four: records collection. Medical records are pulled from every provider who treated the NHL — the hematologist-oncologist, the radiation oncologist, the infusion center, the hospital, the pathology lab. Exposure history is documented in writing — a detailed statement of when, where, how often, and for how long the plaintiff used Roundup, what product they used, what equipment they used, and what protective measures they took or did not take. Witnesses are identified and statements are taken while memories are fresh.
Months one through three: expert retention and case theory development. The toxicologist is retained to address general causation — whether glyphosate can cause non-Hodgkin’s lymphoma. The hematologist-oncologist is retained to address specific causation — whether this plaintiff’s NHL was caused by glyphosate exposure. The industrial hygienist is retained to reconstruct the exposure — how much glyphosate the plaintiff absorbed, through what route, over what period. The product design expert is retained to address feasible alternative designs — whether a safer formulation existed at the time the plaintiff used the product. The case theory is built around the evidence these experts produce, not the other way around.
Months three through twelve: discovery. Written discovery — interrogatories, requests for production, requests for admission — forces the company to produce documents and answer questions under oath. Deppositions — sworn testimony before a court reporter — put the company’s scientists, executives, and safety officers on the record. The internal corporate documents are where the case is won or lost. If discovery produces evidence that Monsanto scientists raised cancer concerns internally and were overruled, that evidence supports design defect liability and punitive damages. If discovery produces evidence that the company knew a safer formulation was feasible and chose not to use it, that evidence is the design defect case.
Year one and beyond: motion practice and trial preparation. The defense will file motions to dismiss — arguing preemption, arguing insufficient causation pleading, arguing the EPA’s determination is a complete defense. Each motion must be briefed, argued, and decided. Expert witnesses will be deposed by the defense — their qualifications, methodology, and opinions will be challenged under Daubert standards. The trial itself — if the case does not settle — is where the jury hears the full story: the exposure, the disease, the corporate documents, the IARC classification, the EPA conflict, the reformulation, and the human cost.
You can learn more about how much a personal injury case is worth from our video library — because understanding value is the first step to making an informed decision.
Your First 72 Hours: A Practical Roadmap
Hour 1 through hour 24: document everything. Write down your complete Roundup use history — the products, the years, the frequency, the areas treated, the equipment used, the protective measures taken or not taken. If you have old containers, receipts, or photographs, set them aside in a safe place. If family members or neighbors witnessed your Roundup use, note their names and contact information. Pull together your medical records — diagnosis date, pathology reports, treatment history, current status.
Hour 24 through hour 48: do not sign anything. If you have received a communication from Bayer, Monsanto, a settlement administrator, or any entity offering to resolve your claim, do not sign it, do not return it, and do not discuss your case with anyone from the company or its representatives. Do not give a recorded statement. Do not post about your case on social media. Do not discuss your diagnosis or your Roundup use in any public forum that the defense can access.
Hour 48 through hour 72: call a lawyer. The preservation letter goes out the day you call. The statute of limitations analysis begins. The settlement evaluation starts. The design defect theory is assessed against your specific facts. This is not a sales pitch — it is a clock. Every day you wait is a day the evidence degrades, a day the settlement opt-out deadline approaches, and a day the company builds its defense. Call our contact page or call 1-888-ATTY-911. The consultation is free. We do not get paid unless we win your case.
If your loved one died from non-Hodgkin’s lymphoma after years of Roundup use, the same roadmap applies — but with additional urgency, because wrongful death claims have their own procedural requirements, including the appointment of a personal representative, and because the evidence of the decedent’s exposure history must be preserved before it disappears with the person who lived it. Our wrongful death practice handles these cases with the specific care they demand.
Frequently Asked Questions
Can I still sue Bayer or Monsanto if I used Roundup and got cancer?
Yes — but the legal theory has changed. The Supreme Court’s June 25, 2026 ruling blocks failure-to-warn claims, which argued the company should have put a cancer warning on the label. But design defect claims — which argue the product’s formulation was unreasonably dangerous — remain legally viable. The Supreme Court’s own opinion left room for these claims. You may also be eligible to participate in the $7.25 billion class-action settlement proceeding in Missouri state court. Each path requires an individualized evaluation of your exposure history, medical records, and legal options.
What is the difference between a failure-to-warn claim and a design defect claim?
A failure-to-warn claim says the product was dangerous and the company should have told you about the danger on the label. A design defect claim says the product was dangerous in its very design — that the formulation itself was unreasonably dangerous, and that a safer alternative design was feasible. The Supreme Court preempted failure-to-warn claims because the EPA approved Roundup’s label without a cancer warning and federal law bars states from imposing different labeling requirements. Design defect claims are not about labeling — they are about the product itself — so FIFRA’s preemption of labeling requirements does not reach them.
How do I know if I qualify for the $7.25 billion settlement?
The settlement framework uses a tier system based on exposure duration, cancer subtype, and treatment history. Claimants with documented non-Hodgkin’s lymphoma and documented Roundup use history are the core population, but the specific tier and value depend on the details of your individual case. The settlement is proceeding in Missouri state court, and opt-out deadlines — the date by which you must decide whether to participate or preserve your right to sue individually — are critical. Missing an opt-out deadline can lock you into a settlement whose terms may not fully value your claim. You need an individualized evaluation before making this decision.
How long do I have to file a Roundup cancer claim in Missouri?
Missouri’s personal injury statute of limitations is five years — among the longest in the nation. For toxic tort cases, the discovery rule may extend the clock further, because the clock often does not begin running until the plaintiff knew or should have known that their injury was caused by the defendant’s product. For a disease like non-Hodgkin’s lymphoma, which can develop years after exposure, the question of when the clock started is often contested and depends on the specific facts of your case. Do not assume you have plenty of time, and do not assume you are too late — the only way to know is to have a lawyer evaluate your specific timeline.
What if I live in North Dakota, Georgia, or Kentucky — do the state shield laws affect me?
Yes. Those three states have enacted legislation specifically shielding Bayer from failure-to-warn liability, adding a state-level barrier on top of the federal preemption ruling. In those states, the design defect path may be your only viable theory, and even that may face additional state-law hurdles. If you live in Missouri or a state without such a shield, your options are broader. The legal landscape is now a patchwork — federal preemption everywhere, plus state-specific shields in some jurisdictions — which makes venue strategy and state-law analysis more important than ever.
Does the Supreme Court ruling mean the EPA says Roundup is safe?
No. The EPA determined that glyphosate is “not likely” to cause cancer in humans when used as directed. That is a regulatory conclusion about labeling requirements under FIFRA — not a scientific finding that the product is safe, and not a finding that glyphosate does not cause cancer. The World Health Organization’s International Agency for Research on Cancer reached the opposite conclusion in 2015, classifying glyphosate as “probably carcinogenic.” The conflict between these two determinations is unresolved, and a jury in a design defect case can be told about both and asked to weigh the evidence. The EPA’s regulatory determination is a defense argument, not a defense verdict.
What evidence do I need to preserve for a Roundup cancer claim?
Four categories: medical records (pathology reports, treatment history, imaging, follow-up surveillance), exposure documentation (purchase receipts, application logs, employment or neighborhood association records, witness statements), product evidence (containers, lot numbers, formulation records for the specific product you used), and corporate documents (obtained through discovery — internal Monsanto/Bayer safety research, marketing materials, communications about cancer risk). The evidence that dies fastest is exposure documentation — memories fade, witnesses relocate, organizational records are discarded. The preservation letter that freezes corporate records goes out the day you call a lawyer.
Is it too late to join the Roundup litigation if I was just diagnosed?
Probably not — but it depends on your state’s statute of limitations and when you discovered the connection between your cancer and Roundup. Missouri’s five-year personal injury deadline, combined with the discovery rule for toxic tort cases, means many people diagnosed recently are still well within the filing window. If you were diagnosed years ago, the analysis is more complex — but the discovery rule may still apply if you only recently learned that Roundup may have caused your cancer. The only way to know for certain is to have a lawyer evaluate your specific timeline. Do not assume you are too late without checking.
What if my loved one died from non-Hodgkin’s lymphoma after using Roundup?
You may have a wrongful death claim, but the procedural requirements are different and more urgent. A personal representative must be appointed — the person Missouri law authorizes to bring the family’s case. The decedent’s exposure history — the most important evidence — must be documented before it disappears with the person who lived it. Family members, coworkers, and neighbors who witnessed the Roundup use must be identified and their statements preserved. The Supreme Court’s preemption ruling applies equally to wrongful death claims — failure-to-warn is preempted, design defect remains viable — but the evidence preservation challenge is greater because the primary witness is no longer available.
How much is a Roundup cancer case worth after the Supreme Court ruling?
The value depends on the legal path you choose and the strength of your specific facts. Settlement participation through the $7.25 billion class-action framework may produce compensation in the $50,000 to $300,000 range for claimants with documented NHL and moderate exposure history. A design defect verdict in a favorable venue with strong causation evidence, compelling corporate documents, and punitive damages can reach $2 million to $50 million or more. The preemption ruling did not eliminate the value of Roundup cases — it bifurcated it. Failure-to-warn claims are now near-worthless as standalone filings. Design defect claims carry higher litigation risk and cost but retain the verdict ceiling that produced outsized awards in pre-ruling cases. Past results depend on the facts of each case and do not guarantee future outcomes.
Why This Firm
We are Attorney911 — The Manginello Law Firm, PLLC. We are Legal Emergency Lawyers. We have been trying cases since July 18, 2001 — more than 24 years. Ralph Manginello, our managing partner, has been licensed since November 6, 1998 — 27 years in courtrooms, including federal court. He was a journalist before he was a lawyer, which means he knows how to find the story the company does not want told. He is admitted to the U.S. District Court, Southern District of Texas, and he takes cases in Missouri with local counsel where required.
Lupe Peña is our associate attorney. He spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He sat across the table from the claimants’ lawyers and helped the insurance company pay as little as possible. Now he sits on your side of the table. He knows how claims are valued, how reserves are set, how IME doctors are selected, how surveillance works, and how delay tactics are deployed — because he used to run those tactics. That inside knowledge is now working for injured clients. Lupe is fluent in Spanish and conducts full consultations in Spanish without an interpreter.
We work on contingency. We charge 33.33% before trial and 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free. We have live staff available 24 hours a day, 7 days a week — not an answering service. When you call, you talk to a person who can help.
We have recovered more than $50 million for our clients. That figure includes a $5 million brain-injury settlement, a $3.8 million amputation settlement, a $2.5 million truck-crash recovery, and millions in trucking wrongful-death cases. Past results depend on the facts of each case and do not guarantee future outcomes — but the track record tells you what kind of fight we bring.
If you used Roundup and developed non-Hodgkin’s lymphoma, the Supreme Court ruling changed your legal landscape — but it did not end your case. The design defect path is open. The settlement is proceeding. The evidence is on a clock. The call is free. Hablamos Español. Call 1-888-ATTY-911 or reach us through our contact page. The day you call is the day the clock starts working for you instead of against you.